Patent US4579828A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4579828A Expired / Lapsed US ⏱️ 0.0 years remaining

Clot activator for serum separation tubes

Assignee: Becton Dickinson and Co
•
Filing: 1983-12-15
•
Granted: 1986-04-01
•
Expires: 2003-12-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An improved clot activator system for reducing the clotting time for blood samples in serum separation tubes, and the like, as well as increasing the degree of clotting, while at the same time, reducing the cost of production. This is achieved by the addition of glass pieces to the tube which pieces are formed in a particular way by a sol-gel process. The particles are pieces of glass, and are a porous substantially rigid amorphous inorganic sponge with substantial reactive surfaces. When a blood sample is introduced into a serum separation tube containing such pieces, the blood enters the interstices of the pieces causing fragmentation thereof, which fragmentation causes sound and shock waves which, in turn, enhance the clotting of the blood.

Inventors

  • 👤 Keramat Ali

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 20:43
CPC Classifications
C; C03; C03C; C03C11/00; G; G01; G01N; G01N33/00; G01N33/48; G01N33/483; G01N33/487; G01N33/49; G01N33/491; G01N33/50; G01N33/86

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 218 words
A process for producing and utilizing a blood clot activator material, characterized by the steps of (a) forming a mixture by admixing ethylsilicate and ethyl alcohol; (b) initiating hydrolysis of the mixture formed from said forming step by adding a reactant selected from the group consisting of ammonia, acetic acid, sulphuric acid, and hydrochloric acid; (c) partially hydrolyzing said mixture from said adding step, by introducing therein less than a stoichiometric quantity of water; (d) maintaining in a first maintaining step said mixture from said partial hydrolysis step at room temperature while stirring for a period of time sufficient to polymerize said ethylsilicate into a solidified form of glass; (e) maintaining in a second maintaining step said solidified glass obtained from said first maintaining step at room temperature for a period of time sufficient to dry said solidified glass; (f) maintaining in a third maintaining step said solidified glass from said second maintaining step at an elevated temperature within the range of between about 110° C. and 120° C. to break down said solidified glass into small pieces; and (g) introducing a quantity of said small pieces from said third maintaining step into each of a plurality of blood collection containers; (h) whereby blood samples subsequently introduced into said plurality of blood collection containers are caused to clot.
Claim 2
Dependent Claim 218 words
A process for producing and utilizing a blood clot activator material, characterized by the steps of (a) forming a mixture by admixing ethylsilicate and ethyl alcohol; (b) initiating hydrolysis of the mixture formed from said forming step by adding a reactant selected from the group consisting of ammonia, acetic acid, sulphuric acid, and hydrochloric acid; (c) partially hydrolyzing said mixture from said adding step, by introducing therein less than a stoichiometric quantity of water; (d) maintaining in a first maintaining step said mixture from said partial hydrolysis step at room temperature while stirring for a period of time sufficient to polymerize said ethylsilicate into a solidified form of glass; (e) maintaining in a second maintaining step said solidified glass obtained from said first maintaining step at room temperature for a period of time sufficient to dry said solidified glass; (f) maintaining in a third maintaining step said solidified glass from said second maintaining step at an elevated temperature within the range of between about 110° C. and 120° C. to break down said solidified glass into small pieces; and (g) introducing a quantity of said small pieces from said third maintaining step into each of a plurality of blood collection containers; (h) whereby blood samples subsequently introduced into said plurality of blood collection containers are caused to clot.
Claim 3
Dependent Claim 30 words
The process of claim 1, further characterized by (a) said forming step being carried out with a mixture of ethylsilicate and ethyl alcohol in the ratio of 1:1 by volume.
Claim 4
Dependent Claim 27 words
The process of claim 1, further characterized by (a) said second maintaining step being carried out for within the range of between about 2 and 3 hours.
Claim 5
Dependent Claim 38 words
The process of claim 1, further characterized by (a) said small pieces from said third maintaining step being of a size within the range of between about 2 millimeters by 2 millimeters and 2 millimeters by 10 millimeters.
Claim 6
Dependent Claim 249 words
In a blood sample collection device having means for activating blood clotting properties comprising (a) a container having an opening; (b) a closure for said opening; (c) a quantity of an amorphous rigid porous glass in said container; wherein the improvement comprises said glass being amorphous porous imperfect glass material obtained by the process of (d) forming a mixture by admixing ethylsilicate and ethyl alcohol; (e) initiating hydrolysis of the mixture formed from said forming step by adding a reactant selected from the group consisting of ammonia, acetic acid, sulphuric acid and hydrochloric acid; (f) partially hydrolyzing said mixture from said adding step, by introducing therein less than a stoichiometric quantity of water; (g) maintaining in a first maintaining step said mixture from said partial hydrolysis step at room temperature while stirring for a period of time sufficient to polymerize said ethylsilicate into a solidified form of glass; (h) maintaining in a second maintaining step said solidified glass obtained from said first maintaining step at room temperature for a period of time sufficient to dry said solidified glass; (i) maintaining in a third maintaining step said solidified glass from said second maintaining step at an elevated temperature within the range of between about 110° C. and 120° C. to break down said solidified glass into small pieces; and (j) introducing a quantity of said small pieces from said third maintaining step into said container opening; (k) whereby a blood sample subsequently introduced into said container is caused to clot.
Claim 7
Dependent Claim 249 words
In a blood sample collection device having means for activating blood clotting properties comprising (a) a container having an opening; (b) a closure for said opening; (c) a quantity of an amorphous rigid porous glass in said container; wherein the improvement comprises said glass being amorphous porous imperfect glass material obtained by the process of (d) forming a mixture by admixing ethylsilicate and ethyl alcohol; (e) initiating hydrolysis of the mixture formed from said forming step by adding a reactant selected from the group consisting of ammonia, acetic acid, sulphuric acid and hydrochloric acid; (f) partially hydrolyzing said mixture from said adding step, by introducing therein less than a stoichiometric quantity of water; (g) maintaining in a first maintaining step said mixture from said partial hydrolysis step at room temperature while stirring for a period of time sufficient to polymerize said ethylsilicate into a solidified form of glass; (h) maintaining in a second maintaining step said solidified glass obtained from said first maintaining step at room temperature for a period of time sufficient to dry said solidified glass; (i) maintaining in a third maintaining step said solidified glass from said second maintaining step at an elevated temperature within the range of between about 110° C. and 120° C. to break down said solidified glass into small pieces; and (j) introducing a quantity of said small pieces from said third maintaining step into said container opening; (k) whereby a blood sample subsequently introduced into said container is caused to clot.
Claim 8
Dependent Claim 15 words
The device of claim 5, further characterized by (a) said container is an evacuated container.
Claim 9
Dependent Claim 30 words
The device of claim 5, further characterized by (a) said forming step being carried out with a mixture of ethylsilicate and ethyl alcohol in the ratio of 1:1 by volume.
Claim 10
Dependent Claim 27 words
The device of claim 5, further characterized by (a) said second maintaining step being carried out for within the range of between about 2 and 3 hours.
Claim 11
Dependent Claim 38 words
The device of claim 5, further characterized by (a) said small pieces from said third maintaining step being of a size within the range of between about 2 millimeters by 2 millimeters and 2 millimeters by 10 millimeters.
Claim 12
Dependent Claim 43 words
The device of claim 5, further characterized by (a) said container is an evacuated serum separation tube having an open end and a closed end; and (b) a thixotropic gel positioned in the closed end of said tube prior to said introducing step.
Claim 13
Dependent Claim 200 words
An amorphous porous imperfect glass material in the form of pieces for introduction into blood sample collection devices for enhancing clot activation of blood samples subsequently introduced into such devices, said glass pieces obtained by the process of (a) forming a mixture by admixing ethylsilicate and ethyl alcohol; (b) initiating hydrolysis of the mixture formed from said forming step by adding a reactant selected from the group consisting of ammonia, acetic acid, sulphuric acid and hydrochloric acid; (c) partially hydrolyzing said mixture from said adding step, by introducing therein less than a stoichiometric quantity of water; (d) maintaining in a first maintaining step said mixture from said partial hydrolysis step at room temperature while stirring for a period of time sufficient to polymerize said ethylsilicate into a solidified form of glass; (e) maintaining in a second maintaining step said solidified glass obtained from said first maintaining step at room temperature for a period of time sufficient to dry said solidified glass; (f) maintaining in a third maintaining step said solidified glass from said second maintaining step at an elevated temperature within the range of between about 110° C. and 120° C. to break down said solidified glass into small pieces.
Claim 14
Dependent Claim 200 words
An amorphous porous imperfect glass material in the form of pieces for introduction into blood sample collection devices for enhancing clot activation of blood samples subsequently introduced into such devices, said glass pieces obtained by the process of (a) forming a mixture by admixing ethylsilicate and ethyl alcohol; (b) initiating hydrolysis of the mixture formed from said forming step by adding a reactant selected from the group consisting of ammonia, acetic acid, sulphuric acid and hydrochloric acid; (c) partially hydrolyzing said mixture from said adding step, by introducing therein less than a stoichiometric quantity of water; (d) maintaining in a first maintaining step said mixture from said partial hydrolysis step at room temperature while stirring for a period of time sufficient to polymerize said ethylsilicate into a solidified form of glass; (e) maintaining in a second maintaining step said solidified glass obtained from said first maintaining step at room temperature for a period of time sufficient to dry said solidified glass; (f) maintaining in a third maintaining step said solidified glass from said second maintaining step at an elevated temperature within the range of between about 110° C. and 120° C. to break down said solidified glass into small pieces.
Claim 15
Dependent Claim 33 words
The blood clot activator material of claim 11, further characterized by (a) said forming step being carried out with a mixture of ethylsilicate and ethyl alcohol in the ratio of 1:1 by volume.
Claim 16
Dependent Claim 30 words
The blood clot activator material of claim 11, further characterized by (a) said second maintaining step being carried out for within the range of between about 2 and 3 hours.
Claim 17
Dependent Claim 41 words
The blood clot activator material of claim 11, further characterized by (a) said small pieces from said third maintaining step being of a size within the range of between about 2 millimeters by 2 millimeters and 2 millimeters by 10 millimeters.

References Cited (Backward Citations)

US3667909A Cited
DE2453813A1 Cited
US4028085A Cited
JPS5328495A Cited
US4153739A Cited
US4257886A Cited
JPS56125240A Cited
US4402927A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-03-31 1989-09-30 1990-04-01 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-03-31 1993-09-30 1994-04-01 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-03-31 1997-09-30 1998-04-01 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag